Molecular Partners AG (MOLN)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Patrick Amstutz
Employees:
180
WAGISTRASSE 14, Z?RICH-SCHLIEREN, V8, 8952
41 44 755 77 00
Molecular Partners AG focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema. MP0420 is a multi-specific DARPin therapy candidate for the SARS-CoV-2 virus. The company also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|